Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.70 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239076 | 0.90 | PTGS1 (0.55) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL24359868 | 0.85 | PTGS1 (0.75) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL24360271 | 0.85 | PTGS1 (0.75) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL928708 | 0.85 | PTGS1 (0.79) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL20215625 | 0.85 | PTGS1 (0.74) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL23639668 | 0.85 | PTGS1 (0.74) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL4408402 | 0.84 | PTGS1 (0.73) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL680902 | 0.83 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL9817253 | 0.83 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL10797351 | 0.83 | PTGS1 (0.76) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723327-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723327-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7592449-B2 | Structural carotenoid analogs for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7320997-B2 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7317008-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMACEUTICALS, INC. (US) | 2008-01-08 | — | — | US | disclosed |